Blowing the Whistle at the FDA, Jan 2001, exposing Dearborn and how OspA causes immunosuppression rather than, "was a vaccine."
 

 

The following is a 3-page summary of what I believe is recoverable, as in “damages” in the “Lyme Disease” crimes.

  

BACKGROUND/INTRODUCTION:   I refer to members of the ALDF.com as the Crooks.  They are:  Allen Steere (formerly at Yale, then Tufts, now Harvard), Robert Schoen (Yale), Dave Persing (formerly at Mayo, then at Corixa, Corixa was purchased by SmithKline, taking all the proprietary vaccine damage and failure data out of the country), Eugene Shapiro (Yale), Larry Zemel (UConn), Henry Feder (UConn), Edward McSweegan (US Navy, then NIH, now “does no work” at the NIH), Durland Fish (friends with McSweegan, first at New York Medical College when the cabal was established, now at Yale), Arthur Weinstein (formerly at NYMC, now at some college in DC), Paul Auwaerter (now at Johns Hopkins, perpetuating the lie), John Nowakowski, John J. Halperin (Long Island Jewish, I think), Raymond Dattwyler (SUNY-SB), Gary Wormser (NYMC), CDC officer Alan Barbour (formerly head of the NIH Rocky Mountain Bioweapons Lab, now at Ucal, Irvine, I believe), CDC officer Barbara Johnson, CDC, (Ft. Collins, Colorado) and some others (like Dave Dennis, who no one can determine why was associated with Crazy Eddie No-Work McSweegan).

 

The ALDF.com was established at NYMC in 1990.  It was a coop between the insurance companies (Kaiser-Permanente, who still has a relationship with the CDC and drafts a lot of their employees from the CDC; Kaiser is also still at NYMC actually writing the MD training protocols and giving tuition kickbacks to whoever signs on as a Kaiser MD-drone) and the DNA patent profiteers [Barbour, Persing, Fish, Yale, Peter Krause (Fikrig-and-Flavell,) etc].  The goal of Big Insurance and the CDC is VACCINES.  Their solution to everything is “prevention.”  The insurance companies wanted a vaccine because they were spending up to $200,000 per year, per patient for IV medication for this chronic encephalitis.  (So, while the crooks say the Lyme victims wanted a vaccine, it was actually the insurance companies.  This is plenty obvious since Lyme is incurable, and the patients would not be screaming about a vaccine, but some medical relief from the chronic misery of Borreliosis and the Imitators.)


PREVIOUS to 1990:  From 1982 to 1989, the Crooks believed Lyme was chronic, neurologic and seronegative.  They pondered why this could be.  Ray Dattwyler investigated whether or not Lyme was like other fungal infections and caused immunosuppression and no antibodies.  He developed a “seronegative T cell assay” for this reason.

 

In 1989, the Crooks published a grand summary (in the Infectious Disease Reviews, their former journal)  and related articles explaining that they observed “significant” relationships between Lyme and MS, and Lyme and ALS, and Lyme and Lupus. They called it the New Great Imitator for this reason.  They also examined and published the scientifically valid Biomarkers, or signs that a person is actually sick, and not relying on subjective testimony or psychiatric brainscramble and bullshit. 

 

In 1990, the CDC published diagnosis guidelines on Lyme stating that one needed to look for NEW IgM bands, because they knew Lyme, as a Relapsing Fever organism, would undergo antigenic variation, thus change antigens over time, thus change antibodies.  There was no ELISA requirement.  The requirement for serodiagnosis was serial or sequential Western Blots to look for new bands.

1988, Alan Barbour applied for a patent for an OspA vaccine.


1991, Erol Fikrig and Richard Flavell developed and later applied for a Flagellin Antibody Method that met the criteria for a “valid” method.  They claimed their SPECIFIC recombinant flagellin DNA detected 17/18 patients or was 94.4% ACCURATE.  They did not use this to qualify their later patent, LYMErix or another OspA vaccine.
 

1992, CDC staff including Barbara Johnson applied for 5 patents with SmithKline in Europe wherein they claim that there are 2 kinds of Lyme, one with the antibodies and one without. (Diseases for which there are no antibodies will not lend themselves to commercialization a la recombinant antigens for vaccines and test kits, so the CDC staff patents would be worthless to SmithKline under normal circumstances.)

1992, Allen Steere went to Europe to narrow the disease definition to only the cases that represented a typical infection, or one that produced antibodies.  Those happened to be only the HLA-linked autoimmune arthritis cases.  Allen Steere is a CDC officer.

There were 2 reports issued by Allen Steere re his time in Germany (1992), which I refer to as Dressler/Steere or the later (current, CDC diagnostic standard) “Dearborn Method,” and the other is called “Antigens in Europe” (or STEERE_IN_EUROPE.htm).  Both are published in non-American (German) journals and therefore were never readily available to be scrutinized by Americans, especially not online thru PubMed, or previous to that, MedLine.

In the Antigens in Europe report, Steere committed research fraud to leave OspA and B (both encoded on the same plasmid, so they would both have to be left out if they were to pharm that plasmid out – there was no other way) out of his proposal for a diagnostic antibody panel (which later became known as the Dearborn panel).  The gist of the criminal act was revealed in this one paragraph:

 

“The group 1 strain of B. burgdorferi, G39/40, used in this study and in the previous study of US patients was isolated from an Ixodes damini tick in Guilford, Connecticut [21].  The group 2 strain, FRG [Federal Republic of Germany], was isolated from Ixodes ricinus near  Cologne [22].  The group 3 strain, IP3, was isolated from Ixodes persulcatus near Leningrad [23].  All three strains used in this study were high passage isolates, which were classified by Richard Marconi (Rocky Mountain Laboratory, Hamilton, MT) using 16S ribosomal RNA sequence determination as described [11, 24].  The recombinant preparations of OspA and OspB used in this study were purified maltose- binding protein-Osp fusion proteins derived from group 1 strain B31 [25].  The fusion proteins contained the full-length OspA or OspB sequence without the lipid moiety or the signal sequence -"

Marconi had said previous to this event, not to use high passage strains because they drop plasmids (and therefore antibodies that are their in a human host would not be detected).  Steere also used recombinant OspA and B without the lipid attached, because the protein ends alone do not produce antibodies.  You have to have the lipid attached to the lipoprotein to determine its true antigenicity.  Having done this, Steere came up with a diagnostic antibody panel that left the two “primary, immunodominant antigens,” OspA and B, out of the diagnostic standard.  (That meant that if you had those 2 antibody bands and 3 others, even with this bogus Dearborn case, you would not be allowed to have a “case” of Lyme.)

 

1993, the Crooks were already involved in Phase I and II of their OspA vaccine trials.  Alan Barbour and Durland Fish published an article called the Social Aspects of Lyme Disease
http://www.actionlyme.org/BARBOURFISHpdf.pdf , and began their campaign to label chronic neurologic Lyme victims as hysterics and hypochondriacs.  Nevertheless, it was revealed in that report that the OspA trials were underway.

So they would have HAD to have known that recombinant OspA caused a chronic Lyme-like illness by 1993, and we can prove they did.

 

1994, CDC hosted a conference (in Dearborn, MI), a consensus conference, to which labs (about 11) across the country were invited to “participate in the proceedings.”

Everyone who participated at the Dearborn Farce of a consensus conference said Steere’s (Dressler/Steere/Fraud in Europe) proposal sucked.  Contributers t6o Dearborn had said Steere’s proposal was anywhere from 8 to 22% accurate.  Gary Wormser reported that this method missed 85% of the cases.  A test that misses 85% of the cases is great for saying, “No vaccine failure, here.”

The Crooks narrowed the disease definition to suit their own commercial products’ bottom line.

 

1998, LYMErix came to market.  The other patent, CDC officer Alan Barbour’s patent, did not make it to market, despite the criminals who participated in that trial lying to the public about its safety and efficacy even worse than the LYMErix, or Yale gang.

A year later, 1999, there were all kinds of adverse events reported which was why the FDA granted us a hearing (held Jan 31, 2001).

 

 

What’s Actually Criminal:  Yale knew LYMErix produced a chronic Lyme-like, New Great Imitator-like outcome.  They threw those vaccine adverse event cases out of their vaccine trial summary (called them “Unconfirmed Lyme” and just did not use those cases in their calculation of safety and efficacy). 

They trashed those victims in the exact same way they trashed the chronic Lyme victims, once they had in mind they would pass off bogus vaccines for a disease that defies the concept of vaccines.

Yale owns a scientifically valid way to detect Lyme in its earliest stage, which would inhibit most of the long term damage.  They did not deploy this method for the LYMErix trial, either. 

OspA was in the end the very thing, the very fungal antigen, the very TLR2-agonist (structure equaling function), that caused the New Great Imitator outcomes of MS, ALS, Lupus, Chronic Fatigue, Cancer, etc.   Yale obstructed discovery in every major disease.

Because Yale lied about the outcome of LYMErix, the same molecule was used as an HIV vaccine.  The HIV-LYMErix vaccine failed (2008) in the same way the LYMErix vaccine and the Tuberculosis vaccines all failed – they caused immunosuppression, no antibodies, and they made the victims more susceptible to other infections.

LYMErix did not produce antibodies.  It is a fungal antigen.  It activates latent herpesviruses, which are basically the main drivers of the MS and Lupus outcomes.  And OspA-induced tolerance to similar TLR2-agonists causing the ALS and Chronic Fatigue outcomes (mycoplasma bear OspA-like antigens).